Zurcher Kantonalbank Zurich Cantonalbank grew its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) by 378.5% during the 4th quarter, Holdings Channel reports. The fund owned 4,555 shares of the company’s stock after buying an additional 3,603 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Krystal Biotech were worth $319,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently modified their holdings of the company. CWM LLC purchased a new stake in shares of Krystal Biotech in the fourth quarter valued at about $4,192,000. Dupont Capital Management Corp acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at about $177,000. Widmann Financial Services Inc. acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at about $34,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at about $229,000. Finally, Parallel Advisors LLC lifted its stake in shares of Krystal Biotech by 212.0% in the fourth quarter. Parallel Advisors LLC now owns 34,036 shares of the company’s stock valued at $2,381,000 after purchasing an additional 23,128 shares during the period. 77.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of KRYS opened at $69.31 on Friday. The stock has a market cap of $1.75 billion, a P/E ratio of -22.21 and a beta of 0.96. The company has a 50-day moving average of $66.25 and a two-hundred day moving average of $61.62. Krystal Biotech, Inc. has a 12-month low of $38.86 and a 12-month high of $102.99.
Several analysts recently commented on KRYS shares. Zacks Investment Research cut shares of Krystal Biotech from a “hold” rating to a “sell” rating in a research note on Wednesday, March 2nd. Bank of America started coverage on shares of Krystal Biotech in a research note on Tuesday, January 18th. They issued a “buy” rating and a $110.00 price objective for the company. HC Wainwright reduced their price objective on shares of Krystal Biotech from $124.00 to $107.00 and set a “buy” rating for the company in a research note on Monday, February 28th. Guggenheim cut their target price on shares of Krystal Biotech from $114.00 to $101.00 in a research report on Tuesday, March 29th. Finally, The Goldman Sachs Group cut their target price on shares of Krystal Biotech from $125.00 to $93.00 and set a “buy” rating for the company in a research report on Tuesday, March 1st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $96.67.
Krystal Biotech Profile (Get Rating)
Krystal Biotech, Inc, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
- Get a free copy of the StockNews.com research report on Krystal Biotech (KRYS)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.